Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
120.43
+4.72 (4.08%)
At close: May 12, 2025, 4:00 PM
118.51
-1.92 (-1.59%)
After-hours: May 12, 2025, 7:15 PM EDT
Neurocrine Biosciences Employees
Neurocrine Biosciences had 1,800 employees as of December 31, 2024. The number of employees increased by 400 or 28.57% compared to the previous year.
Employees
1,800
Change (1Y)
400
Growth (1Y)
28.57%
Revenue / Employee
$1,340,333
Profits / Employee
$169,889
Market Cap
11.92B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1,800 | 400 | 28.57% |
Dec 31, 2023 | 1,400 | 200 | 16.67% |
Dec 31, 2022 | 1,200 | 300 | 33.33% |
Dec 31, 2021 | 900 | 55 | 6.51% |
Dec 31, 2020 | 845 | 145 | 20.71% |
Dec 31, 2019 | 700 | 115 | 19.66% |
Dec 31, 2018 | 585 | 185 | 46.25% |
Dec 31, 2017 | 400 | 204 | 104.08% |
Dec 31, 2016 | 196 | 76 | 63.33% |
Dec 31, 2015 | 120 | 26 | 27.66% |
Dec 31, 2014 | 94 | 13 | 16.05% |
Dec 31, 2013 | 81 | 3 | 3.85% |
Dec 31, 2012 | 78 | 7 | 9.86% |
Dec 31, 2011 | 71 | 5 | 7.58% |
Dec 31, 2010 | 66 | 1 | 1.54% |
Dec 31, 2009 | 65 | -60 | -48.00% |
Dec 31, 2008 | 125 | -10 | -7.41% |
Dec 31, 2007 | 135 | -132 | -49.44% |
Dec 31, 2006 | 267 | -321 | -54.59% |
Dec 31, 2005 | 588 | 203 | 52.73% |
Dec 31, 2004 | 385 | 40 | 11.59% |
Dec 31, 2003 | 345 | 69 | 25.00% |
Dec 31, 2002 | 276 | 54 | 24.32% |
Dec 31, 2001 | 222 | 34 | 18.09% |
Dec 31, 2000 | 188 | 37 | 24.50% |
Dec 31, 1999 | 151 | 2 | 1.34% |
Dec 31, 1998 | 149 | 41 | 37.96% |
Dec 31, 1997 | 108 | 5 | 4.85% |
Dec 31, 1996 | 103 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
NBIX News
- 4 days ago - Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgroups - PRNewsWire
- 6 days ago - Neurocrine Biosciences to Present at Upcoming Investor Conferences in May - PRNewsWire
- 6 days ago - Neurocrine Biosciences' Ingrezza Q1 Sales Prove Resilient, Analysts Boost Price Target - Benzinga
- 6 days ago - Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia - PRNewsWire
- 7 days ago - Neurocrine Biosciences, Inc. (NBIX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance - PRNewsWire
- 7 days ago - Neurocrine Biosciences Announces New Survey Revealing Need for Routine Screening and Earlier Diagnosis for People Living with Tardive Dyskinesia - PRNewsWire
- 12 days ago - Nxera Pharma's Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia - GlobeNewsWire